ImmuCell Reports 46% Increase in Q3 Sales
News related to:ImmuCell · 1 min read
PORTLAND, Maine, Oct. 12, 2026 /CourierPR/ -- ImmuCell, an animal health biologics company, reported a significant increase in its third-quarter sales figures, marking a strong performance in the market. According to the company, total sales for the three months ended September 30, 2026, amounted to $8.0 million, a 46.0% increase from the same period in 2025, when sales were $5.47 million. Domestic sales, which account for a substantial portion of the company's revenue, saw a 29.2% rise, reaching $6.9 million compared to $5.32 million in the previous year.
Olivier te Boekhorst, the President and CEO of ImmuCell, attributed the growth to the company's strategic expansion of its sales team and enhanced commercial execution.
The company's product portfolio showed broad-based growth, with key products performing particularly well. Tri-Shield®, a core product, saw a 51.0% increase in sales over the third quarter of 2025. Dual-Force®, another significant product, experienced a 36.0% growth. The company's recently launched functional feed line also contributed to the growth, with sales increasing by 37.0% over the same period.
ImmuCell's total sales for the nine months ended September 30, 2026, reached $25.6 million, marking a 27.8% increase from the $20.0 million recorded in the same period of 2025.
Looking ahead, the company plans to host a conference call on Friday, November 13, 2026, at 9:00 AM ET. Interested parties can access the call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). A teleconference replay will be available until November 20, 2026, at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2589057. The call can also be joined via webcast at app.webinar.net/JL8AEda3K5D.
The company's forward-looking statements are subject to various risks and uncertainties, as detailed in its filings with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K, and Current Reports on Form 8-K.